Related Experiment Video
Updated: Jun 22, 2026

Detection of Mitochondria Membrane Potential to Study CLIC4 Knockdown-induced HN4 Cell Apoptosis In Vitro
Published on: July 17, 2018
Monoclonal antibodies against human bit1, an apoptosis-associated mitochondrial protein
Wei Hua1, Biliang Chen, Wei Zhang
1Department of Obstetrics and Gynecology, Xijing Hospital, The Fourth Military Medical University, Xi'an, P.R. China.
Abstract:
Bit1 (Bcl2-inhibitor of transcription 1) is a mitochondrial protein that was found eliciting caspase-independent apoptosis when released into the cytoplasm, where it forms a complex with AES (amino-terminal enhancer of split). In our research, cytosolic fraction of suspended cultured human ovarian cancer cells was taken as immunogen, and recombined protein Bit1-His was used to select hybridomas. Two hybridoma cell lines secreting monoclonal antibodies (MAbs) against Bit1 were obtained by routine murine hybridoma technique. The MAbs were characterized by indirect ELISA, Western blotting, and immunohistochemistry, and it was found that they recognized distinct epitopes. The sandwich method to detect sera Bit1 was established, and a distinct difference of sera Bit1 between the ovarian carcinoma patients and normal controls was found. To conclude, these MAbs against human Bit1 may be useful for exploring the tumor apoptosis mechanism and monitoring patients' clinical data.
Insights
Researchers developed monoclonal antibodies (MAbs) targeting Bcl2-inhibitor of transcription 1 (Bit1). These antibodies are valuable for studying ovarian cancer apoptosis and monitoring patient data.
Area of Science:
- Biochemistry
- Molecular Biology
- Oncology
Background:
- Bcl2-inhibitor of transcription 1 (Bit1) is a mitochondrial protein.
- Bit1 induces caspase-independent apoptosis upon cytoplasmic release.
- Bit1 interacts with amino-terminal enhancer of split (AES) in the cytoplasm.
Purpose of the Study:
- To develop monoclonal antibodies (MAbs) against human Bit1.
- To characterize the generated MAbs and their epitopes.
- To establish a method for detecting serum Bit1 levels and assess its clinical relevance in ovarian cancer.
Main Methods:
- Murine hybridoma technique was employed to generate MAbs against Bit1.
- Recombinant Bit1-His protein and cytosolic fractions of ovarian cancer cells were used.
- MAbs were characterized using indirect ELISA, Western blotting, and immunohistochemistry.
- A sandwich assay was developed for serum Bit1 detection.
Main Results:
- Two hybridoma cell lines secreting MAbs against Bit1 were successfully established.
- The MAbs were confirmed to recognize distinct epitopes on Bit1.
- A significant difference in serum Bit1 levels was observed between ovarian carcinoma patients and healthy controls.
- The sandwich assay demonstrated effectiveness in detecting serum Bit1.
Conclusions:
- The developed MAbs against human Bit1 show promise for investigating tumor apoptosis mechanisms.
- These MAbs could serve as a tool for monitoring clinical data in ovarian cancer patients.
- Further research utilizing these MAbs may enhance understanding and management of ovarian cancer.
Related Concept Videos
The Intrinsic Apoptotic Pathway
Cellular Injury V: Apoptosis and Autophagy
